Drug intelligence / Profile preview

phillygenin

Development stage
Preclinical
Lead developer
First Affiliated Hospital of Nanchang University
Modality
Small Molecules
Administration
Oral
01

Overview

Phillygenin is a natural lignan monomer isolated from the fruit of *Forsythia suspensa* (Lianqiao). It exhibits a wide range of pharmacological activities, including anti-inflammatory, antioxidant, hepatoprotective, and anticancer properties. Phillygenin acts as a direct agonist of the G-protein coupled bile acid receptor 1 (GPBAR1/TGR5) and an inhibitor of maternal embryonic leucine zipper kinase (MELK) and Toll-like receptor 4 (TLR4). It has been shown to activate AMP-activated protein kinase (AMPK) and suppress downstream inflammatory pathways, including the TLR4/MyD88/NF-κB and NLRP3 inflammasome cascades. Phillygenin is being investigated preclinically for the treatment of various conditions, including sepsis-associated acute kidney injury (SA-AKI), diabetic nephropathy, ulcerative colitis, severe acute pancreatitis, arthritis, neuropathic pain, pancreatic cancer, and hepatocellular carcinoma.

Other names
(-)-phillygenin(+)-phillygeninepipinoresinol methyl etherphillygenol
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)GPBAR1MELK (Maternal embryonic leucine zipper kinase)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on phillygenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phillygenin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call